R Squared Ltd Has $310,000 Holdings in Recursion Pharmaceuticals, Inc. $RXRX

R Squared Ltd lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 347.8% during the second quarter, HoldingsChannel.com reports. The fund owned 61,257 shares of the company’s stock after purchasing an additional 47,577 shares during the period. R Squared Ltd’s holdings in Recursion Pharmaceuticals were worth $310,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of RXRX. Brighton Jones LLC raised its position in shares of Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after acquiring an additional 6,699 shares during the period. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock valued at $38,000 after acquiring an additional 2,026 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Recursion Pharmaceuticals by 27.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 24,230 shares of the company’s stock valued at $128,000 after acquiring an additional 5,278 shares during the period. Cambridge Investment Research Advisors Inc. raised its position in shares of Recursion Pharmaceuticals by 33.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 117,120 shares of the company’s stock valued at $620,000 after acquiring an additional 29,136 shares during the period. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at approximately $67,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on RXRX. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.25.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares of the company’s stock, valued at $3,688,447.44. This trade represents a 5.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.43% of the stock is owned by corporate insiders.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $6.04 on Friday. The stock has a market capitalization of $2.62 billion, a P/E ratio of -3.39 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a 50 day moving average of $5.18 and a 200-day moving average of $5.18. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals’s revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.40) earnings per share. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.